Dir
Peter Feinberg is a Director at Immuneering Corp (NASDAQ:IMRX), a clinical-stage biopharmaceutical company focused on AI-driven drug discovery.[[1]](https://www.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-4447187)[[2]](https://www.marketbeat.com/instant-alerts/insider-buying-immuneering-nasdaqimrx-director-acquires-20000-shares-of-stock-2026-01-14/) On January 12, 2026, he purchased 20,000 shares of Class A Common Stock at a weighted average price of $4.3452, totaling $86,904, increasing his direct ownership to 156,766 shares.[[1]](https://www.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-4447187) He also holds significant indirect ownership through entities including PF Associates L.P. (392,242 shares), PEF LLC (476,615 shares), and S4K Investments LLC (135,441 shares).[[1]](https://www.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-4447187)
Feinberg has a history of active investment in Immuneering, with multiple purchases over the past five years, including 25,000 shares on March 22, 2024, and no recorded sales, resulting in total ownership of approximately 1,141,064 shares valued at over $5 million as of recent filings.[[4]](https://www.gurufocus.com/insider/178418/peter-feinberg) Previously, he served as a director at Vascular Biogenics Ltd (VBLT).[[4]](https://www.gurufocus.com/insider/178418/peter-feinberg) His ongoing buys signal confidence in Immuneering amid the company's clinical advancements, such as promising Phase 2a data for pancreatic cancer treatment atebimetinib.[[1]](https://www.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-4447187)
View full insider profile →
